Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY-NC-NDEndocrine Journal

Iodothyronine deiodinases: biological roles and clinical implications

  • Ichiro Yamauchi
  • Yoriko Sakane
Read full textPDFDOICite

Abstract

Iodothyronine deiodinases (DIOs) are key regulators of thyroid hormone action. Three types of DIOs, including type 1 (D1), 2 (D2), and 3 (D3), coordinate the local and systemic availability of T3. D2 primarily catalyzes the activating conversion of T4 to T3, whereas D3 mainly catalyzes the inactivating conversion of T4 to reverse T3 (rT3) and T3 to diiodothyronine (T2). D1 has a relatively low affinity for T4 and contributes less to T4 activation but preferentially catalyzes the conversion of rT3 to T2. Thyroid hormones promote D1 and D3 expression, whereas D2 activity is transcriptionally regulated via several pathways such as cAMP and post-translationally through ubiquitin-dependent proteasomal degradation. Evidence from knockout and overexpressing mouse models and human genetic variants has clarified the physiological roles of DIOs in thyroid hormone economy. Reduced D1 activity increases serum rT3 levels, D2 enhances local thyroid hormone action and contributes to circulating T3 production, and D3 decreases circulating T3 and T4 levels while increasing rT3 levels. DIO dysregulation is implicated in several clinical conditions. GH-related disorders potentially alter thyroid function via D2-mediated mechanisms. In adrenal insufficiency, thyroid function may exhibit elevated serum fT3 levels without TSH suppression. Additionally, resistance to thyroid hormone β can be associated with bezafibrate-induced consumptive hypothyroidism through increased hepatic D3 expression. This review summarizes current knowledge on the biological properties and clinical implications of DIOs and highlights their significant role in the regulation of thyroid hormone action.

Related

  1. MicroRNAs in Cutaneous Melanoma: Biological Roles, Clinical Utility, and Future Directions
    Adrian-Ilie Pașcu, Maximilian-Vlad Muntean, Claudia Diana Gherman +4
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. POSTN-expressing cancer-associated fibroblasts: roles in the tumor microenvironment and clinical implications
    Xiufang Wang, Yongchang Zhao
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Non-Invasive Prenatal Testing in Donor-Oocyte Pregnancies: Biological Determinants, Algorithmic Limitations and Clinical Implications
    Michele Miscia, Irene Pesaresi, Benedetta Dini +3
    Molecular Diagnosis & TherapyPeer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
  4. The role of patient age in fertility preservation among women with breast cancer: biological mechanisms and clinical implications
    Martina Placidi, Manuela Ludovisi, Laura Pizzorno +3
    Journal of Assisted Reproduction and GeneticsPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsPMC
  5. SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS
    Paola Carolina RABESQUINI MARCELINO DA SILVA, Igor CEREJO TAVARES DA SILVA DE ALMEIDA, Joaquim GASPARINI DOS SANTOS +7
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ

Cite

BibTeXRIS
BibTeX
@article{yamauchi2026iodothyronine,
  title = {{Iodothyronine deiodinases: biological roles and clinical implications}},
  author = {Ichiro Yamauchi and Yoriko Sakane},
  journal = {Endocrine Journal},
  year = {2026},
  month = sep,
  doi = {10.1507/endocrj.ej26-0178},
  url = {https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0178/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Iodothyronine deiodinases: biological roles and clinical implications
AU  - Ichiro Yamauchi
AU  - Yoriko Sakane
PY  - 2026
DA  - 2026/09/02
JO  - Endocrine Journal
DO  - 10.1507/endocrj.ej26-0178
UR  - https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0178/_article
AB  - Iodothyronine deiodinases (DIOs) are key regulators of thyroid hormone action. Three types of DIOs, including type 1 (D1), 2 (D2), and 3 (D3), coordinate the local and systemic availability of T3. D2 primarily catalyzes the activating conversion of T4 to T3, whereas D3 mainly catalyzes the inactivating conversion of T4 to reverse T3 (rT3) and T3 to diiodothyronine (T2). D1 has a relatively low affinity for T4 and contributes less to T4 activation but preferentially catalyzes the conversion of rT3 to T2. Thyroid hormones promote D1 and D3 expression, whereas D2 activity is transcriptionally regulated via several pathways such as cAMP and post-translationally through ubiquitin-dependent proteasomal degradation. Evidence from knockout and overexpressing mouse models and human genetic variants has clarified the physiological roles of DIOs in thyroid hormone economy. Reduced D1 activity increases serum rT3 levels, D2 enhances local thyroid hormone action and contributes to circulating T3 production, and D3 decreases circulating T3 and T4 levels while increasing rT3 levels. DIO dysregulation is implicated in several clinical conditions. GH-related disorders potentially alter thyroid function via D2-mediated mechanisms. In adrenal insufficiency, thyroid function may exhibit elevated serum fT3 levels without TSH suppression. Additionally, resistance to thyroid hormone β can be associated with bezafibrate-induced consumptive hypothyroidism through increased hepatic D3 expression. This review summarizes current knowledge on the biological properties and clinical implications of DIOs and highlights their significant role in the regulation of thyroid hormone action.
SN  - 1348-4540
SN  - 0918-8959
ER  -